FR21C1031I2 - N4-PHENYL-QUINAZOLIN-4-AMINE DERIVATIVES AND SIMILAR COMPOUNDS AS ERBB KINASE TYROSINE TYPE I INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES - Google Patents

N4-PHENYL-QUINAZOLIN-4-AMINE DERIVATIVES AND SIMILAR COMPOUNDS AS ERBB KINASE TYROSINE TYPE I INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES

Info

Publication number
FR21C1031I2
FR21C1031I2 FR21C1031C FR21C1031C FR21C1031I2 FR 21C1031 I2 FR21C1031 I2 FR 21C1031I2 FR 21C1031 C FR21C1031 C FR 21C1031C FR 21C1031 C FR21C1031 C FR 21C1031C FR 21C1031 I2 FR21C1031 I2 FR 21C1031I2
Authority
FR
France
Prior art keywords
treatment
inhibitors
quinazolin
phenyl
similar compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1031C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of FR21C1031I1 publication Critical patent/FR21C1031I1/fr
Application granted granted Critical
Publication of FR21C1031I2 publication Critical patent/FR21C1031I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)

Abstract

This invention provides compounds of Formula (I), wherein B, G, A, E, R 1 , R 2 , R 3 , m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
FR21C1031C 2005-11-15 2021-07-20 N4-PHENYL-QUINAZOLIN-4-AMINE DERIVATIVES AND SIMILAR COMPOUNDS AS ERBB KINASE TYROSINE TYPE I INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES Active FR21C1031I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73628905P 2005-11-15 2005-11-15
US81701906P 2006-06-28 2006-06-28
PCT/US2006/044431 WO2007059257A2 (en) 2005-11-15 2006-11-15 N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases

Publications (2)

Publication Number Publication Date
FR21C1031I1 FR21C1031I1 (en) 2021-08-27
FR21C1031I2 true FR21C1031I2 (en) 2022-07-15

Family

ID=38022019

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1031C Active FR21C1031I2 (en) 2005-11-15 2021-07-20 N4-PHENYL-QUINAZOLIN-4-AMINE DERIVATIVES AND SIMILAR COMPOUNDS AS ERBB KINASE TYROSINE TYPE I INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES

Country Status (29)

Country Link
US (6) US8648087B2 (en)
EP (2) EP2090575B1 (en)
JP (2) JP5134548B2 (en)
KR (1) KR101086967B1 (en)
CN (2) CN102887891B (en)
AT (2) ATE507224T1 (en)
AU (2) AU2006315383B2 (en)
BR (2) BRPI0618668B1 (en)
CA (2) CA2632194C (en)
CY (2) CY1110583T1 (en)
DE (2) DE602006021645D1 (en)
DK (2) DK1971601T3 (en)
ES (2) ES2335535T3 (en)
FI (1) FIC20210022I1 (en)
FR (1) FR21C1031I2 (en)
HK (2) HK1119174A1 (en)
HU (1) HUS2100028I1 (en)
IL (2) IL239149A (en)
LT (1) LTC1971601I2 (en)
LU (1) LUC00217I2 (en)
NL (1) NL301113I2 (en)
NO (1) NO342413B1 (en)
PL (2) PL2090575T3 (en)
PT (2) PT2090575E (en)
RU (2) RU2592703C9 (en)
SG (1) SG152230A1 (en)
SI (2) SI1971601T1 (en)
WO (1) WO2007059257A2 (en)
ZA (1) ZA200804498B (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2399427T3 (en) 2003-08-14 2013-04-01 Array Biopharma, Inc. Quinazoline analogs as inhibitors of tyrosine kinase receptors
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
PT2090575E (en) * 2005-11-15 2011-06-06 Array Biopharma Inc Processes and intermediates for the preparation of n4-phenyl-quinazoline-4-amine derivatives
TWI417095B (en) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
SG174774A1 (en) * 2006-09-11 2011-10-28 Curis Inc Quinazoline based egfr inhibitors containing a zinc binding moiety
EP2061772A4 (en) * 2006-09-11 2011-06-29 Curis Inc Multi-functional small molecules as anti-proliferative agents
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
EP2162445B1 (en) * 2007-06-05 2013-11-27 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
PT2200985E (en) 2007-09-14 2011-07-21 Ortho Mcneil Janssen Pharm 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
UA100126C2 (en) 2007-09-14 2012-11-26 Аддекс Фарма С.А. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1, 4'] bipyridinyl-2'-ones
JP5433579B2 (en) 2007-09-14 2014-03-05 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 1,3-disubstituted-4-phenyl-1H-pyridin-2-one
CN101861316B (en) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
EP2532657B9 (en) 2008-10-14 2017-04-19 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
RU2517181C2 (en) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Indole and benzomorpholine derivatives as modulator of metabotropic glutamate receptors
BRPI0921333A2 (en) 2008-11-28 2015-12-29 Addex Pharmaceuticals Sa indole and benzoxazine derivatives as metabotropic glutamate receptor modulators
CA2746354A1 (en) 2008-12-11 2010-06-17 Respivert Limited P38 map kinase inhibitors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI1010831A2 (en) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa 1,2,4-triazolo [4,3-a] pyridine derivatives and their as positive allosteric modulators of mglur2 receptors
KR101753826B1 (en) 2009-05-12 2017-07-04 얀센 파마슈티칼즈, 인코포레이티드 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
US8586581B2 (en) 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
WO2011082271A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted triazolo-pyrimidine compounds
CN102382106A (en) * 2010-08-30 2012-03-21 黄振华 Aniline substituted quinazoline derivative
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2649069B1 (en) 2010-11-08 2015-08-26 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
ES2536433T3 (en) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
JP2014156400A (en) * 2011-05-24 2014-08-28 Astellas Pharma Inc Labeled derivative for image diagnosis of tumor
RS56608B1 (en) * 2011-10-14 2018-02-28 Array Biopharma Inc Solid dispersion
WO2013056183A1 (en) * 2011-10-14 2013-04-18 Array Biopharma Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions contianing them
ES2855142T3 (en) 2012-03-23 2021-09-23 Array Biopharma Inc Compounds for use in the treatment of brain metastases in a patient with ErbB2 + breast cancer
KR101645112B1 (en) 2013-03-06 2016-08-02 아스트라제네카 아베 Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
SG11201508532VA (en) * 2013-03-15 2015-11-27 Deciphera Pharmaceuticals Llc N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
WO2015008844A1 (en) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Therapeutic agent for fgfr inhibitor-resistant cancer
DK3023100T3 (en) * 2013-07-18 2019-05-27 Taiho Pharmaceutical Co Ltd ANTITUM MEDICINE FOR INTERMITTING ADMINISTRATION OF FGFR HARMFUL
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
HUE045610T2 (en) 2014-01-21 2020-01-28 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
MX2016009471A (en) 2014-01-21 2016-10-13 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use.
CA3081443A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of Michigan Small molecule inhibitors of egfr and pi3k
CA2980888C (en) 2015-03-31 2018-03-06 Taiho Pharmaceutical Co., Ltd. Crystal of 3,5-disubstituted benzene alkynyl compound
CN107141293B (en) * 2016-03-01 2022-09-23 上海医药集团股份有限公司 Nitrogen-containing heterocyclic compound, preparation method, intermediate, composition and application
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20180118719A (en) 2016-03-04 2018-10-31 다이호야쿠힌고교 가부시키가이샤 Preparations and compositions for the treatment of malignant tumors
CN106117182B (en) * 2016-06-20 2019-08-30 中国药科大学 Quinazoline-N- phenethyl tetrahydroisoquinolicompounds compounds and its preparation method and application
KR102270620B1 (en) 2016-09-01 2021-06-30 난징 트렌스테라 바이오사이언스즈 컴퍼니 리미티드 Inhibitors of fibroblast growth factor receptors and uses thereof
US11525008B2 (en) 2016-09-22 2022-12-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of lung cancer
US11040984B2 (en) * 2016-12-30 2021-06-22 Medshine Discovery Inc. Quinazoline compound for EGFR inhibition
WO2018201016A1 (en) 2017-04-28 2018-11-01 Cascadian Therapeutics, Inc. Treatment of her2 positive cancers
US11578074B2 (en) 2017-09-01 2023-02-14 Shanghai Pharmaceuticals Holding Cd., Ltd. Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application
DK3769765T3 (en) 2018-03-19 2024-05-13 Taiho Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION CONTAINING SODIUM ALKYL SULFATE
TWI811358B (en) 2018-05-08 2023-08-11 大陸商迪哲（江蘇）醫藥股份有限公司 Erbb receptor inhibitors
WO2019214651A1 (en) * 2018-05-08 2019-11-14 南京明德新药研发有限公司 Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective her2 inhibitors and application thereof
CA3099776A1 (en) * 2018-09-18 2020-03-26 Suzhou Zanrong Pharma Limited Quinazoline derivatives as antitumor agents
CN109942576B (en) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib and preparation method of intermediate
CN111825604A (en) * 2019-04-16 2020-10-27 宁波药腾医药科技有限公司 Synthesis method of cartinib and intermediate product thereof
WO2021088987A1 (en) * 2019-11-08 2021-05-14 南京明德新药研发有限公司 Salt form serving as selective her2 inhibitor, and crystal forms and application thereof
CN115052881A (en) * 2020-02-03 2022-09-13 勃林格殷格翰国际有限公司 [1,3] diazino [5,4-d ] pyrimidines as HER2 inhibitors
US20230126204A1 (en) * 2020-02-03 2023-04-27 Boehringer Ingelheim International Gmbh [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
WO2021179274A1 (en) * 2020-03-13 2021-09-16 Suzhou Zanrong Pharma Ltd. ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS
US11608343B2 (en) * 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
TW202214641A (en) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Her2 mutation inhibitors
US20240116921A1 (en) * 2020-12-22 2024-04-11 Enliven Therapeutics, Inc. Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2
KR20230155422A (en) 2020-12-22 2023-11-10 메카니스틱 테라퓨틱스 엘엘씨 Substituted aminobenzylheteroaryl compounds as EGFR and/or PI3K inhibitors
PE20240327A1 (en) * 2021-04-13 2024-02-22 Nuvalent Inc HETEROCYCLES WITH AMINO SUBSTITUTION TO TREAT CANCERS WITH EGFR MUTATIONS
KR20240027048A (en) * 2021-06-26 2024-02-29 어레이 바이오파마 인크. HER2 mutation inhibitor
KR102598580B1 (en) * 2021-07-16 2023-11-06 한양대학교 에리카산학협력단 Novel method for preparing nitroalkene compounds
WO2023081637A1 (en) 2021-11-02 2023-05-11 Enliven Therapeutics, Inc. Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
WO2023185793A1 (en) * 2022-03-28 2023-10-05 江苏恒瑞医药股份有限公司 Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof
CN117384162A (en) * 2022-05-17 2024-01-12 浙江文达医药科技有限公司 Selective HER2 inhibitors
WO2024027695A1 (en) * 2022-08-04 2024-02-08 微境生物医药科技(上海)有限公司 Compounds as her2 inhibitors
CN115650975A (en) * 2022-08-23 2023-01-31 四川大学华西医院 Protein degradation targeting chimeric compound for targeted degradation of human epidermal growth factor receptor 2 and application thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (en) 1972-02-29 1973-08-27 Pfizer NEW DERIVATIVES OF QUINOLEINE, QUINOXALINE AND QUINAZOLINE ER PHARMACEUTICAL COMPOSITION CONTAINING THEM
DE2653005A1 (en) * 1975-12-03 1977-06-08 Sandoz Ag NEW ORGANIC COMPOUNDS, THEIR USE AND PRODUCTION
US6743782B1 (en) 1987-10-28 2004-06-01 Wellstat Therapeutics Corporation Acyl deoxyribonucleoside derivatives and uses thereof
US5204348A (en) 1988-10-06 1993-04-20 Mitsui Toatsu Chemicals Inc. Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components
CA1340821C (en) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5517680A (en) 1992-01-22 1996-05-14 Ericsson Inc. Self correction of PST simulcast system timing
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
JP3398152B2 (en) * 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー 1N-alkyl-N-arylpyrimidineamine and derivatives thereof
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (en) 1994-11-12 1997-12-01 Zeneca Ltd
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
AR004010A1 (en) 1995-10-11 1998-09-30 Glaxo Group Ltd HETERO CYCLIC COMPOUNDS
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
SK285141B6 (en) 1996-02-13 2006-07-07 Astrazeneca Uk Limited Use of quinazoline derivative, quinazoline derivative, process for preparation thereof and pharmaceutical composition containing thereof
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
KR100489174B1 (en) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-anilinoquinazoline derivatives
DK0892789T4 (en) 1996-04-12 2010-04-06 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ID19609A (en) 1996-07-13 1998-07-23 Glaxo Group Ltd HETEROSICLIC COMPOUNDS
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
DE19735682A1 (en) 1997-08-19 1999-02-25 Basf Ag Single step production of a benzothiadiazinone di:oxide
IL135636A0 (en) 1997-11-11 2001-05-20 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
JP2002505288A (en) 1998-03-02 2002-02-19 コセンシス，インコーポレイテッド Substituted quinazolines and analogs and their uses
US6017922A (en) 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
EA003786B1 (en) 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
BR9916904A (en) 1999-01-13 2001-10-30 Warner Lambert Co Benzo heterocycles and their use as demek inhibitors
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
AU763242B2 (en) 1999-09-21 2003-07-17 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
PT1287001E (en) 2000-06-06 2004-12-31 Pfizer Prod Inc UTIOUS THYROFEN DERIVATIVES AS ANTICANCERIGENE AGENTS
MXPA02012870A (en) 2000-06-22 2003-05-14 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cell growth.
TW200914443A (en) 2000-06-30 2009-04-01 Glaxo Group Ltd Process for preparing substituted quinazolinyl furanaldehyde
MXPA02012903A (en) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors.
CA2411160A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
EP1337513A1 (en) 2000-11-02 2003-08-27 AstraZeneca AB 4-substituted quinolines as antitumor agents
SE0100569D0 (en) 2001-02-20 2001-02-20 Astrazeneca Ab New compounds
AU2002338286A1 (en) * 2001-04-10 2002-10-28 Leo Pharma A/S Novel aminophenyl ketone derivatives
WO2003040108A1 (en) 2001-11-03 2003-05-15 Astrazeneca Ab Quinazoline derivatives as antitumor agents
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
US6756006B1 (en) 2002-03-05 2004-06-29 Peter Levijoki Method of forming sculptured designs onto a substrate
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
JP2006515871A (en) 2003-01-23 2006-06-08 ティー．ケイ． シグナル リミテッド Irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and use thereof
PE20040945A1 (en) 2003-02-05 2004-12-14 Warner Lambert Co PREPARATION OF SUBSTITUTED QUINAZOLINES
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CA2527017A1 (en) 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
WO2005007083A2 (en) 2003-06-18 2005-01-27 Smithkline Beecham Corporation Chemical compounds
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
ES2399427T3 (en) 2003-08-14 2013-04-01 Array Biopharma, Inc. Quinazoline analogs as inhibitors of tyrosine kinase receptors
RU2328287C2 (en) 2003-08-18 2008-07-10 Пфайзер Продактс Инк. Antineoplastic agents erbb2 intake scheme
DE10337942A1 (en) 2003-08-18 2005-03-17 Merck Patent Gmbh aminobenzimidazole derivatives
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
GB0321648D0 (en) 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
JP2007505873A (en) 2003-09-16 2007-03-15 アストラゼネカ アクチボラグ Quinazoline derivatives as tyrosine kinase inhibitors
WO2005044302A1 (en) 2003-11-06 2005-05-19 Pfizer Products Inc. Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
KR100735639B1 (en) 2004-12-29 2007-07-04 한미약품 주식회사 Quinazoline derivatives inhibiting the growth of cancer cell and preparation thereof
PT2090575E (en) * 2005-11-15 2011-06-06 Array Biopharma Inc Processes and intermediates for the preparation of n4-phenyl-quinazoline-4-amine derivatives

Also Published As

Publication number Publication date
PT1971601E (en) 2010-01-26
US20180271824A1 (en) 2018-09-27
DK2090575T3 (en) 2011-05-23
BR122018075851B1 (en) 2022-01-11
RU2011122539A (en) 2012-12-10
IL248993B (en) 2018-11-29
CA2755268A1 (en) 2007-05-24
DK1971601T3 (en) 2010-02-08
CN102887891A (en) 2013-01-23
US20230142839A1 (en) 2023-05-11
US20110034689A1 (en) 2011-02-10
ES2335535T3 (en) 2010-03-29
AU2006315383B2 (en) 2011-06-02
IL239149A (en) 2016-11-30
PL1971601T3 (en) 2010-03-31
FR21C1031I1 (en) 2021-08-27
US9693989B2 (en) 2017-07-04
CY1112754T1 (en) 2016-02-10
US20170252317A1 (en) 2017-09-07
AU2006315383A1 (en) 2007-05-24
AU2010202330B2 (en) 2012-07-19
CN102887891B (en) 2016-03-09
ATE446294T1 (en) 2009-11-15
DE602006009968D1 (en) 2009-12-03
SI2090575T1 (en) 2011-08-31
SI1971601T1 (en) 2010-03-31
US20210008023A1 (en) 2021-01-14
EP2090575A1 (en) 2009-08-19
JP2009515988A (en) 2009-04-16
NO20082598L (en) 2008-08-06
WO2007059257A3 (en) 2007-08-23
ZA200804498B (en) 2009-07-29
US8648087B2 (en) 2014-02-11
CA2632194A1 (en) 2007-05-24
PT2090575E (en) 2011-06-06
JP5232841B2 (en) 2013-07-10
LUC00217I2 (en) 2022-10-07
IL239149A0 (en) 2015-07-30
WO2007059257A8 (en) 2007-07-12
BRPI0618668A2 (en) 2011-09-06
WO2007059257A2 (en) 2007-05-24
NL301113I2 (en) 2021-08-03
RU2008118417A (en) 2009-12-27
RU2428421C2 (en) 2011-09-10
US10780073B2 (en) 2020-09-22
KR20080070064A (en) 2008-07-29
HUS2100028I1 (en) 2021-08-30
DE602006021645D1 (en) 2011-06-09
NL301113I1 (en) 2021-07-01
LTPA2021516I1 (en) 2021-08-10
US20140023643A1 (en) 2014-01-23
PL2090575T3 (en) 2011-09-30
FIC20210022I1 (en) 2021-07-09
CA2755268C (en) 2013-12-31
CN101356171A (en) 2009-01-28
HK1129678A1 (en) 2009-12-04
JP5134548B2 (en) 2013-01-30
EP1971601A2 (en) 2008-09-24
RU2592703C2 (en) 2016-07-27
AU2010202330A1 (en) 2010-07-01
JP2010270154A (en) 2010-12-02
LTC1971601I2 (en) 2022-10-25
CA2632194C (en) 2012-01-03
KR101086967B1 (en) 2011-11-29
CY1110583T1 (en) 2015-04-29
IL248993A0 (en) 2017-01-31
BRPI0618668B1 (en) 2021-09-21
ES2364901T3 (en) 2011-09-16
RU2592703C9 (en) 2016-10-20
EP1971601B1 (en) 2009-10-21
EP2090575B1 (en) 2011-04-27
HK1119174A1 (en) 2009-02-27
SG152230A1 (en) 2009-05-29
ATE507224T1 (en) 2011-05-15
NO342413B1 (en) 2018-05-22

Similar Documents

Publication Publication Date Title
FR21C1031I2 (en) N4-PHENYL-QUINAZOLIN-4-AMINE DERIVATIVES AND SIMILAR COMPOUNDS AS ERBB KINASE TYROSINE TYPE I INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
CY1112402T1 (en) GLUTAMIC RECEPTOR AMPLIFIERS
CY1107005T1 (en) HETROPYROCYCLIC COMPOUNDS AND THEIR USES AS COMPETITORS OF GLUTAMIC TRANSITIONAL RECEPTORS
HK1101178A1 (en) Alkynyl derivatives as modulators of metabotropic glutamate receptors
UY29927A1 (en) SUBSTITUTED DERIVATIVES OF 5-FENIL-2-TIOXO-IMIDAZOLIN-4-ONA AND 5-FENIL-2-AMINO-IMIDAZOLIDIN-4-ONA AND ITS SALTS, COMPOSITIONS AND APPLICATIONS
BRPI0508051A (en) heteroarylaminopyrazole derivatives usable for the treatment of diabetes
SE0203713D0 (en) Novel compounds
MX2007011847A (en) Pyrimidindione derivatives as prokineticin 2 receptor antagonists.
EA200600071A1 (en) Derivatives of N-phenylpyrazine and Methods for the Prevention or Treatment of Diseases Associated with 5HT-Receptor
UA97235C2 (en) Quinazoline and fused pyrimidine derivatives as erbb inhibitors
SE0303488D0 (en) New use 1X
SE0303419D0 (en) New use 11